Late-onset Parkinsonism in NFκB/c-Rel-deficient mice

Brain

Volumn 135, Issue 9, 2012, Pages 2750-2765

  Baiguera, Cristina ^a   Alghisi, Manuela ^a   Pinna, Annalisa ^b,c   Bellucci, Arianna ^a   De Luca, Maria Antonietta ^c   Frau, Lucia ^b,c   Morelli, Micaela ^b,c   Ingrassia, Rosaria ^a   Benarese, Marina ^a   Porrini, Vanessa ^a   Pellitteri, Michele ^d   Bertini, Giuseppe ^d   Fabene, Paolo Francesco ^d   Sigala, Sandra ^a   Spillantini, Maria Grazia ^e   Liou, Hsiou Chi ^f   Spano, Pier Franco ^a,g   Pizzi, Marina ^a,g  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

l DOPA; motor impairments; NF B c Rel; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BENSERAZIDE; DOPA; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; SODIUM CHLORIDE; TRANSCRIPTION FACTOR REL; TYROSINE 3 MONOOXYGENASE;

AGING; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BASAL AMYGDALA; BASAL GANGLION; BODY WEIGHT; BRADYKINESIA; BRAIN CORTEX; CELL ACTIVATION; CELL MOTILITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GAIT DISORDER; HIPPOCAMPUS; IMMUNOREACTIVITY; LEWY BODY; LOCOMOTION; MAGNOCELLULAR NUCLEUS; MESENCEPHALON; MICROGLIA; MOTOR ACTIVITY; MOUSE; MUSCLE RIGIDITY; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; SEPTUM PELLUCIDUM; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

EID: 84866377694     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws193     Document Type: Article

References (64)

1. Ahn HJ, Hernandez CM, Levenson JM, Lubin FD, Liou HC, Sweatt JD. c-Rel, an NF-kappaB family transcription factor, is required for hippo-campal long-term synaptic plasticity and memory formation. Learn Mem 2008; 15: 539-49.
2. Arbuthnott GW, Wickens J. Space, time and dopamine. Trends Neurosci 2007; 30: 62-9.
3. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23: 228-42.
4. Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, Spano P. From a-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res 2012. In press.
5. Bernard D, Quatannens B, Begue A, Vandenbunder B, Abbadie C. Antiproliferative and antiapoptotic effects of crel may occur within the same cells via the up-regulation of manganese superoxide dismu-tase. Cancer Res 2001; 61: 2656-64.
6. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 1998; 18: 3251-60.
7. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
8. Camandola S, Mattson MP. NF-kappa B as a therapeutic target in neu-rodegenerative diseases. Expert Opin Ther Targets 2007; 11: 123-32.
9. Cardozo-Pelaez F, Song S, Parthasarathy A, Hazzi C, Naidu K, Sanchez-Ramos J. Oxidative DNA damage in the aging mouse brain. Mov Disord 1999; 14: 972-80.
10. Chen C, Edelstein LC, Gé linas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20: 2687-95.
11. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol 2011; 10: 1108-18.
12. Chuang CS, Su HL, Cheng FC, Hsu SH, Chuang CF, Liu CS. Quantitative evaluation of motor function before and after engraftment of dopa-minergic neurons in a rat model of Parkinson's disease. J Biomed Sci 2010; 17: 9.
13. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010; 43: 225-32.
14. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione per-oxidase, glial cells and Parkinson's disease. Neuroscience 1993; 52: 1-6.
15. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
16. Echtay KS. Mitochondrial uncoupling proteins-what is their physiological role? Free Radic Biol Med 2007; 43: 1351-71.
17. Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol 1997; 144: 4-9.
18. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003; 991: 1-14.
19. Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW. Astrocytes and Parkinson's disease. Prog Brain Res 1992; 94: 429-36.
20. Franklin K, Paxinos G. The mouse brain in Stereotaxic Coordinates, Compact 2nd edn. San Diego, CA: Academic Press; 2008.
21. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2007; 104: 18754-59.
22. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, et al. Oxidant stress evoked by pacemaking in dopa-minergic neurons is attenuated by DJ-1. Nature 2010; 468: 696-700.
23. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97: 1634-58.
24. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97.
25. Ho JW, Ho PW, Liu HF, So DH, Chan KH, Tse ZH, et al. UCP4 is a target effector of NF-kB c-Rel pro-survival pathway against oxidative stress. Free Radic Biol Med 2012; 53: 383-94.
26. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 1997; 94: 7531-36.
27. Hutson CB, Lazo CR, Mortazavi F, Giza CC, Hovda D, Chesselet MF. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma 2011; 28: 1783-801.
28. Inta I, Paxian S, Maegele I, Zhang W, Pizzi M, Spano P, et al. Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. J Neurosci 2006; 26: 12896-903.
29. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 2642-47.
30. King MA, Scotty N, Klein RL, Meyer EM. Particle detection, number estimation, and feature measurement in gene transfer studies: optical fractionator stereology integrated with digital image processing and analysis. Methods 2002; 28: 293-99.
31. Koopmans GC, Deumens R, Brook G, Gerver J, Honig WM, Hamers FP, et al. Strain and locomotor speed affect over-ground locomotion in intact rats. Physiol Behav 2007; 92: 993-1001.
32. Kwok KH, Ho PW, Chu AC, Ho JW, Liu HF, Yiu DC, et al. Mitochondrial UCP5 is neuroprotective by preserving mitochondrial membrane potential, ATP levels, and reducing oxidative stress in MPP + and dopa-mine toxicity. Free Radic Biol Med 2010; 49: 1023-35.
33. Lees AJ. L-dopa treatment and Parkinson's disease. Q J Med 1986; 59: 535-47.
34. Levenson JM, Choi S, Lee SY, Cao YA, Ahn HJ, Worley KC, et al. A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel. J Neurosci 2004; 24: 3933-43.
35. LeWitt P. Recent advances in CSF biomarkers for Parkinson's disease. Parkinsonism Relat Disord 2012; 18: S49-51.
36. Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, Liou ML. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999; 11: 361-71.
37. Lv Z, Jiang H, Xu H, Song N, Xie J. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm 2011; 118: 361-9.
38. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neu-rodegenerative disorders. J Clin Invest 2001; 107: 247-54.
39. Meissner W, Harnack D, Reese R, Paul G, Reum T, Ansorge M, et al. High-frequency stimulation of the subthalamic nucleus enhances stri-atal dopamine release and metabolism in rats. J Neurochem 2003; 85: 601-9.
40. Mirza B, Hadberg H, Thomsen P, Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000; 95: 425-32.
41. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999; 22: 123-44.
42. O'Riordan KJ, Huang IC, Pizzi M, Spano P, Boroni F, Egli R, et al. Regulation of nuclear factor kappaB in the hippocampus by group I metabotropic glutamate receptors. J Neurosci 2006; 26: 4870-79.
43. Pifl C, Hornykiewicz O. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int 2006; 49: 519-24.
44. Pizzi M, Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur J Pharmacol 2006; 545: 22-8.
45. Pizzi M, Goffi F, Boroni F, Benarese M, Perkins SE, et al. Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1beta. J Biol Chem 2002; 277: 20717-23.
46. Pizzi M, Sarnico I, Boroni F, Benarese M, Steimberg N, Mazzoleni G, et al. NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ 2005; 12: 761-72.
47. Rozas G, Ló pez-Martín E, Guerra MJ, Labandeira- García JL. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 1998; 83: 165-75.
48. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fisher D, Arredondo M, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegen-eration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008; 105: 18578-83.
49. Sarnico I, Boroni F, Benarese M, Sigala S, Lanzillotta A, Battistin L, et al. Activation of NF-kappaB p65/c-Rel dimer is associated with neuroprotection elicited by mGlu5 receptor agonists against MPP(+) toxicity in SK-N-SH cells. J Neural Transm 2008; 115: 669-76.
50. Sarnico I, Lanzillotta A, Boroni F, Benarese M, Alghisi M, Schwaninger M, et al. NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischaemia. J Neurochem 2009; 108: 475-85.
51. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999; 5: 554-9.
52. Sian-Hü lsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2010; 118: 939-57.
53. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866-8.
54. Song YJ, Halliday GM, Holton JL, Lashley T, O'Sullivan SS, McCann H, et al. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol 2009; 68: 1073-83.
55. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-73.
56. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 2011; 198: 221-31.
57. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med 2011; 1: a009316.
58. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 2007; 103: 17-37.
59. Valerio A, Dossena M, Bertolotti P, Boroni F, Sarnico I, Faraco G, et al. Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription. Stroke 2009; 40: 610-7.
60. Vandeputte C, Taymans JM, Casteels C, Coun F, Ni Y, Van Laere K, et al. Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci 2010; 11: 92.
61. Vlamings R, Visser-Vandewalle V, Koopmans G, Joosten EA, Kozan R, Kaplan S, et al. High frequency stimulation of the subthalamic nucleus improves speed of locomotion but impairs forelimb movement in Parkinsonian rats. Neuroscience 2007; 148: 815-23.
62. Wilson CJ, Callaway JC. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 2000; 83: 3084-100.
63. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011; 26: S1-58.
64. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005; 19: 533-42.